---
title: "KalVista制药 (KALV.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/KALV.US/norm.md"
symbol: "KALV.US"
name: "KalVista制药"
parent: "https://longbridge.com/zh-CN/quote/KALV.US.md"
datetime: "2026-05-20T20:23:02.321Z"
locales:
  - [en](https://longbridge.com/en/quote/KALV.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KALV.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KALV.US/norm.md)
---

# KalVista制药 (KALV.US) — 财务报表

## 利润表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -1.12 | -0.9846 | -0.9183 | -0.9052 | -0.8748 |
| ROE | -353.04% | -173.71% | - | -110.22% | -85.28% |
| 营业收入 | 1.43M | - | 13.69M | - | - |
| 净利润 | -60.10M | -52.23M | -49.48M | -42.27M | -40.44M |
| 营业利润 | -59.01M | -55.03M | -46.05M | -45.81M | -44.22M |
| 毛利率 | -1004.63% | - | 3.41% | - | - |
| 净利率 | -4214.31% | - | -361.39% | - | - |
| 利润含金量 | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 资产与负债 | 215.50M | 250.77M | 339.93M | 160.83M | 200.20M |
| 权益乘数 | 5.28 | 2.63 | 20.00 | 1.20 | 1.16 |
| 每股净资产 | 0.8103 | 1.92 | 0.3363 | 3.10 | 4.01 |
| 资产周转率 | 0.0069 | - | - | - | - |
| 现金及短投 | 191.47M | 220.62M | 309.16M | 135.78M | 174.27M |
| 存货与应收 | - | - | 458000.00 | - | - |
| 长期投资 | 7.23M | 7.53M | 12.29M | 7.90M | 7.96M |
| 净债务 | -53.00M | -108.43M | -26.58M | -129.56M | -168.02M |

## 现金流量表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 经营现金流 | -54.50M | -40.36M | - | -39.64M | -40.22M |
| 投资现金流 | 21.26M | -3.33M | - | 48.67M | 37.16M |
| 融资现金流 | 23.21M | 4.66M | - | 295000.00 | 3.00M |
| 自由现金流 | -31.98M | -18.90M | - | -28.26M | -26.89M |
| 现金流充裕率 | -18793.79% | -14364.41% | - | -36705.56% | -191523.81% |
| 举债与偿债 | - | - | - | - | - |
| 资本支出 | -290000.00 | -281000.00 | - | -108000.00 | -21000.00 |